Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.
about
Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.Pharmacotherapy of end-stage renal disease.Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice.A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency.Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.Insulin degludec: pharmacokinetics in patients with renal impairment.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Current therapeutic approaches in the management of hyperglycemia in chronic renal disease.The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy.Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure.Long-term impact of chronic hemodialysis on glycemic control and serum lipids in insulin-treated type 2-diabetic patients.Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.Metabolic control and vascular diseases under oral antidiabetic drug versus insulin therapy and/or diet alone during the first year of hemodialysis in type 2 diabetic patients with ESRD.A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus.
P2860
Q31025919-6142DCFA-3751-4D37-AB86-A6CD570AE3BCQ33531889-1BDB6D98-E067-42DE-BAF1-3C671D454E8AQ35671873-4B1DEDA7-7037-48F3-851B-2F7E50AE258EQ36188834-5D976131-80A4-4612-AD8E-C08674E319FEQ36249553-9ACEA74A-C151-4B24-9E36-293765EFBFB9Q37127547-CDA5D5F1-6040-499A-B66C-7719AA1D7FBAQ37352359-188D649F-0454-477D-8070-33A78EF304C3Q37506526-E1B82991-1A07-4E76-B0DE-CA9237E578B9Q38012068-AFEA6C5B-6A82-4B3C-8394-4194A557F5ECQ38054558-DD095FEB-EF76-46DD-8352-D70C3BCCFED6Q38086611-FA4EF8F6-083B-4928-922A-F415244C82CDQ39160771-81E7078D-A85C-4076-9B2E-46260FE6ADF1Q41030612-1A97D7FD-9A00-4343-8D96-D4A346AEF021Q42157131-DB2D67E3-D8E8-4D31-857A-23C15362840AQ46548079-8BC8FD71-831E-4652-A9A5-6357835E44ADQ46563222-5D2EC932-A2DB-4B47-A11F-B910EADF04BDQ51394933-F4D8059B-FCC7-4DD4-8CEE-2A34400BA442Q55162068-8C2B9B3F-DD64-439B-9BF8-67D92373EC89
P2860
Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Impact of diabetic nephropathy ...... n in type 1 diabetic patients.
@en
Impact of diabetic nephropathy ...... n in type 1 diabetic patients.
@nl
type
label
Impact of diabetic nephropathy ...... n in type 1 diabetic patients.
@en
Impact of diabetic nephropathy ...... n in type 1 diabetic patients.
@nl
prefLabel
Impact of diabetic nephropathy ...... n in type 1 diabetic patients.
@en
Impact of diabetic nephropathy ...... n in type 1 diabetic patients.
@nl
P2093
P356
P1433
P1476
Impact of diabetic nephropathy ...... n in type 1 diabetic patients.
@en
P2093
P304
P356
10.2337/DIACARE.24.5.886
P407
P577
2001-05-01T00:00:00Z